Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Selective use of radioactive iodine in intermediate-risk papillary thyroid cancer.

Nixon IJ, Patel SG, Palmer FL, Dilorenzo MM, Tuttle RM, Shaha A, Shah JP, Ganly I.

Arch Otolaryngol Head Neck Surg. 2012 Dec 1;138(12):1141-6. doi: 10.1001/jamaoto.2013.760.

PMID:
23403514
2.

Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?

Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly I.

Surgery. 2012 Dec;152(6):1096-105. doi: 10.1016/j.surg.2012.08.034.

PMID:
23158181
3.

Predicting outcome and directing therapy for papillary thyroid carcinoma.

Kim S, Wei JP, Braveman JM, Brams DM.

Arch Surg. 2004 Apr;139(4):390-4; discussion 393-4.

PMID:
15078706
4.
5.

Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope.

Podnos YD, Smith DD, Wagman LD, Ellenhorn JD.

J Surg Oncol. 2007 Jul 1;96(1):3-7.

PMID:
17567872
6.

[Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].

Gemsenjäger E, Heitz PU, Martina B, Schweizer I.

Praxis (Bern 1994). 2000 Nov 2;89(44):1779-97. German.

PMID:
11109916
7.

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Mazzaferri EL, Jhiang SM.

Am J Med. 1994 Nov;97(5):418-28. Erratum in: Am J Med 1995 Feb;98(2):215.

PMID:
7977430
8.

Treatment patterns of aging Americans with differentiated thyroid cancer.

Park HS, Roman SA, Sosa JA.

Cancer. 2010 Jan 1;116(1):20-30. doi: 10.1002/cncr.24717.

9.

Survival impact of treatment options for papillary microcarcinoma of the thyroid.

Lin HW, Bhattacharyya N.

Laryngoscope. 2009 Oct;119(10):1983-7. doi: 10.1002/lary.20617.

PMID:
19655332
10.

Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.

Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE.

Prostate. 2009 Mar 1;69(4):352-62. doi: 10.1002/pros.20889.

PMID:
19016478
11.

Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.

Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI.

Cancer. 2003 Mar 1;97(5):1186-94.

12.

Prognostic factors in mortality and morbidity in patients with differentiated thyroid cancer.

Witt RL, McNamara AM.

Ear Nose Throat J. 2002 Dec;81(12):856-63.

PMID:
12516384
13.

Role of RAI in the management of incidental N1a disease in papillary thyroid cancer.

Wang LY, Palmer FL, Migliacci JC, Nixon IJ, Shaha AR, Shah JP, Tuttle RM, Patel SG, Ganly I.

Clin Endocrinol (Oxf). 2015 Jun 3. doi: 10.1111/cen.12828. [Epub ahead of print]

14.

Treatment for microcarcinoma of the thyroid--clinical experience.

Küçük NO, Tari P, Tokmak E, Aras G.

Clin Nucl Med. 2007 Apr;32(4):279-81.

PMID:
17413573
15.

The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB.

Cancer. 1998 Jan 15;82(2):375-88.

PMID:
9445196
16.

Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer.

Beasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman JL.

Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):825-8.

PMID:
12117344
17.

Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country.

Sugitani I, Toda K, Yamamoto N, Sakamoto A, Fujimoto Y.

World J Surg. 2010 Jun;34(6):1265-73. doi: 10.1007/s00268-009-0305-y.

PMID:
19953247
18.

An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.

Yovino S, Kwok Y, Krasna M, Bangalore M, Suntharalingam M.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1438-43.

PMID:
16029805
19.

Graves' disease and thyroid cancer.

Behar R, Arganini M, Wu TC, McCormick M, Straus FH 2nd, DeGroot LJ, Kaplan EL.

Surgery. 1986 Dec;100(6):1121-7.

PMID:
3787468
20.

Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer.

Haigh PI, Urbach DR, Rotstein LE.

Ann Surg Oncol. 2005 Jan;12(1):81-9. Epub 2004 Dec 27.

PMID:
15827782

Supplemental Content

Support Center